Evekeo is a medication containing amphetamine sulfate, used to treat attention deficit hyperactivity disorder (ADHD) in individuals aged 3 to 17 years and narcolepsy in adults [1]. It is available in tablet form [1].
When does Evekeo's patent exclusivity expire?
The patent exclusivity for Evekeo has largely expired. DrugPatentWatch.com indicates that the patent expiry for Evekeo occurred around 2017-2018 [2]. This means that generic versions of amphetamine sulfate tablets are likely available.
How does Evekeo work for ADHD and narcolepsy?
Evekeo, like other amphetamine medications, is a central nervous system stimulant. It is thought to work by affecting neurotransmitters in the brain, specifically dopamine and norepinephrine, which play a role in attention, impulse control, and wakefulness [1].
What are the common side effects of Evekeo?
Common side effects associated with Evekeo can include decreased appetite, insomnia, dry mouth, weight loss, and stomach pain [1]. Less common but potentially serious side effects may involve cardiovascular issues, psychiatric problems, and slowed growth in children [1].
Are there alternatives to Evekeo for ADHD?
For ADHD, alternative treatments include other stimulant medications, such as methylphenidate-based drugs, and non-stimulant medications [3]. Behavioral therapy and lifestyle adjustments are also important components of ADHD management [3].
Who manufactures Evekeo?
Evekeo was originally developed by Depomed Inc. [4]. Commercial rights may have changed hands since its initial approval.